Arteriovenous Plasma Multiomics in Patients With Disorders of Consciousness

Transient Ischemic Attack Clinical Trial

Official title:

Arteriovenous Plasma Multiomics and Inflammatory Factors in Patients With Disorders of Consciousness

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06403176
• Other study ID #: plasma multiomics
• Status: Completed
• Start date: May 1, 2022
• Est. completion date: April 30, 2024

Study information

• Verified date: March 2022
• Source: First Affiliated Hospital of Zhejiang University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

In order to determine the abnormal cerebral metabolism in the pathological state, we compared the blood of internal jugular vein, superior vena cava and radial artery during central venous catheterization. Metabonomics, proteomics and inflammatory factor microarray were used to detect the material differences in arteriovenous blood of patients with disorders of consciousness. At the same time, we concurrently compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis.

Description:

Background:It is unclear what substances the brain needs to ingest for its activity under pathological conditions

Method:The uptake and release of substances by the brain were observed by comparing arterial blood with internal jugular vein blood;The characteristics of brain metabolites were observed by comparing internal jugular vein blood with superior vena cava blood. Compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis.

Objective:By analyzing different substances, this paper briefly describes the pathological mechanism of patients with disorders of consciousness, and looks for potential prognostic biomarkers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: April 30, 2024
• Est. primary completion date: March 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1.Patients with consciousness disorder caused by various severe brain injuries

Exclusion Criteria:

1. Patients who have been judged brain dead

2. There are persistent epileptic activity, inhibition or seizure inhibition patterns

3. Recent fever, abnormal liver and kidney function

4. Previous history of neurological or mental illness

5. Have a history of tumor

6. Inflammatory bowel diseases, hyperlipidemia, gastritis

Related Conditions & MeSH terms

• Consciousness Disorders
• Disorders of Consciousness
• Ischemic Attack, Transient
• Transient Ischemic Attack

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Zhejiang University	Hanzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital of Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient clinical outcome	The patients were followed up for 12 months after blood collection to observe the clinical outcome	12 months